3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
206
Colonic Neoplasms
89
Rectal Neoplasms
88
Stomach Neoplasms
57
Pancreatic Neoplasms
49
Neoplasms
42
Esophageal Neoplasms
42
Neoplasm Metastasis
39
Unspecified Adult Solid Tumor, Protocol Specific
30
Lung Neoplasms
28
Glioblastoma
27
Brain Neoplasms
26
Carcinoma, Non-Small-Cell Lung
24
Central Nervous System Neoplasms
23
Glioma
22
Small Cell Lung Carcinoma
21
Neuroblastoma
20
Astrocytoma
18
Adenocarcinoma Of Esophagus
18
Esophageal Squamous Cell Carcinoma
17
Gliosarcoma
16
Breast Neoplasms
15
Rhabdomyosarcoma
13
Oligodendroglioma
12
Sarcoma
11
Adenocarcinoma
10
Medulloblastoma
9
Carcinoma, Hepatocellular
9
Sarcoma, Ewing
8
Gastrointestinal Neoplasms
8
Interventions
pembrolizumab
3
Nivolumab
2
vicriviroc
1
relatlimab
1
copanlisib
1
binimetinib
1
Oxaliplatin
1
Leucovorin
1
Irinotecan
1
Fluorouracil
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Spinocerebellar Degenerations
×
Irinotecan
×
Clear all
NCT03374254
2024-11-21
KEYNOTE-651
Merck Sharp & Dohme LLC
Phase 1
Completed
116 enrolled
18 charts